Pemigatinib is a medication used primarily for the treatment of certain types of cancer, specifically for advanced or metastatic cholangiocarcinoma (bile duct cancer) that has a fibroblast growth factor receptor 2 (FGFR2) genetic alteration. It is an oral selective FGFR inhibitor that works by targeting and inhibiting the activity of FGFR2, which is involved in the growth and survival of cancer cells.

By blocking this receptor, pemigatinib can help slow the growth of the cancer or shrink tumors. It has been approved by the U.S. Food and Drug Administration (FDA) for patients with previously treated, unresectable, or metastatic cholangiocarcinoma that is FGFR2 fusion-positive.